Disc Medicine Launches $350 Million Stock and Pre-Funded Warrant Offering

By Public Technologies
  • Disc Medicine launched a proposed $350 million underwritten public offering of common stock or, at certain investors' option, pre-funded warrants.
  • Underwriters would receive a 30-day option to purchase up to $52.5 million in additional common stock.
  • Proceeds would fund research and clinical development, potential bitopertin commercialization, other pre-commercialization activities and general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191601PRIMZONEFULLFEED9848758) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.